Clinical Trial Update: Pembrolizumab in Untreated Extensive SCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update of pembrolizumab for untreated extensive-stage small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Small Cell Lung Cancer (SCLC) | Phase 2 | Status: COMPLETED